Text Size
62 studies found for:    Alzheimer's disease | United States, Tennessee

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 200 mg/day;   Drug: Placebo
2 Completed
Has Results 		A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Dimebon;   Drug: Placebo
3 Terminated A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Bapineuzumab
4 Terminated A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: FK962
5 Active, not recruiting Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)
Condition: Alzheimer Disease
Interventions: Drug: alphatocopherol;   Drug: Selenium;   Drug: Placebo replacement for vitamin E;   Drug: Placebo replacement for Selenium
6 Terminated
Has Results 		An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Dimebon
7 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab;   Drug: Placebo Control
8 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab;   Drug: Placebo Control
9 Completed A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Conditions: Mild-to-moderate Alzheimer's Disease;   Alzheimer's Disease
Interventions: Drug: SB-742457 15mg;   Drug: SB-742457 35mg;   Drug: Placebo;   Drug: donepezil 5-10mg
10 Completed
Has Results 		Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine 4.6 mg/24 h (5 cm^2);   Drug: Rivastigmine 9.5 mg/24 h (10 cm^2);   Drug: Rivastigmine 13.3 mg/24 h (15 cm^2);   Drug: Placebo
11 Recruiting An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Condition: Alzheimer's Disease
Interventions: Drug: MK-8931;   Drug: Placebo
12 Completed Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Rosiglitazone XR (extended release) oral tablets
13 Completed
Has Results 		Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
Condition: Alzheimer Disease
Interventions: Drug: Rivastigmine 5 cm^2;   Drug: Rivastigmine 10 cm^2;   Drug: Rivastigmine 15 cm^2;   Drug: Placebo to 15 cm^2 patch;   Drug: Placebo to 10 cm^2 patch
14 Recruiting Alzheimer's Disease, Caregiving, and Social Networks
Condition: Alzheimer's Disease
Intervention:
15 Completed Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Conditions: Alzheimer's Disease;   Dementia, Alzheimer Type
Intervention: Drug: rivastigmine transdermal patch
16 Completed A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: PF-04447943;   Drug: Placebo
17 Completed Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rosiglitazone Extended Release 2mg;   Drug: Rosiglitazone Extended Release 8mg;   Other: Placebo
18 Completed SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
Condition: Alzheimer's Disease
Intervention: Drug: SGS742
19 Completed A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
Condition: Alzheimer´s Disease
Interventions: Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%);   Other: Placebo solution
20 Completed A 24 Week Open-Label Extension to Study CENA713DUS44
Condition: Alzheimer's Disease
Interventions: Drug: ENA713;   Drug: Rivastigmine transdermal patch 15 cm2
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years